01:10 , Aug 11, 2017 |  BC Innovations  |  Strategy

The flip-side of immunotherapy

In the smaller print of last week’s deal between IFM Therapeutics Inc. and Bristol-Myers Squibb Co. was the latest example of a growing trend of companies aiming to draw extra value out of a cancer...
23:55 , Feb 28, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Pancreatic cancer Patient, cell culture and mouse studies suggest inhibiting IL-35 could help treat metastatic pancreatic ductal carcinoma (PDAC). In 123 PDAC patients, high levels of EBI3 and IL-12A in primary tumors were associated...
07:00 , Mar 14, 2016 |  BioCentury  |  Finance

Abingworth's early action

Abingworth's venture deal flow in the past 12 months reveals a clear preference for getting in early on companies that are generating pipelines of first- or best-in-class products. The latest biotech to match the profile...
07:00 , Mar 27, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Various

Indication Target/marker/pathway Summary Licensing status Publication and contact information Various Autoimmune disease; infectious disease IL-35 Mouse studies suggest enhancing IL-35-producing B cell activity could help treat autoimmunity, whereas blocking production could help treat infections. In...